Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life

NCT00814658 is registered in ClinicalTrials.gov with Janssen-Cilag Farmaceutica Ltda. as lead sponsor.

NCT NCT00814658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00814658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life
Lead sponsor
Janssen-Cilag Farmaceutica Ltda.
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2008
Completion date
October 31, 2009
Enrollment
22 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

dementia